Table 1.
Clinical characteristics of the Physicians’ Health Study prostate cancer cohort
| All (n=1430) | Non-PCSM (n=1225) | PCSM (n=205) | ||
|---|---|---|---|---|
| Age at diagnosis, y | ||||
| Mean (sd) | 70.5 (7.7) | 70.5 (7.6) | 70.8 (8.2) | |
| Median | 70.5 | 70.4 | 70.9 | |
| Range | 45.5–100.9 | 50.9–100.9 | 45.5–92.5 | |
| Gleason score, n (%) | ||||
| 2–4 | 107 (7.5) | 101 (8.2) | 6 (2.9) | |
| 5, 6 | 555 (38.8) | 519 (42.4) | 36 (17.6) | |
| 3+4 (or 7) | 273 (19.1) | 243 (19.8) | 30 (14.6) | |
| 4+3 | 151 (10.6) | 129 (10.5) | 22 (10.7) | |
| 8–10 | 192 (13.4) | 127 (10.4) | 65 (31.7) | |
| Missing | 152 (10.6) | 106 (8.7) | 46 (22.4) | |
| Clinical stage, n (%) | ||||
| T1/T2 | 1166 (81.5) | 1050 (85.7) | 116 (56.6) | |
| T3 | 67 (4.7) | 46 (3.8) | 21 (10.2) | |
| T4/N1/M1 | 83 (5.8) | 25 (2.0) | 58 (28.3) | |
| Missing | 114 (8.0) | 104 (8.5) | 10 (4.9) | |
| PSA at diagnosis, n (%) | ||||
| <4 | 116 (8.1) | 112 (9.1) | 4 (2.0) | |
| 4–9.9 | 558 (39.0) | 531 (43.3) | 27 (13.2) | |
| 10–19.9 | 206 (14.4) | 184 (15.0) | 22 (10.7) | |
| ≥20 | 136 (9.5) | 103 (8.4) | 33 (16.1) | |
| Missing (pre-PSA era) | 217 (15.2) | 136 (11.1) | 81 (39.5) | |
| Missing | 197 (13.8) | 159 (13.0) | 38 (18.5) | |
| Primary therapy, n (%) | ||||
| Radical prostatectomy | 576 (40.3) | 531 (43.3) | 45 (22.0) | |
| Radiation therapy | 371 (25.9) | 322 (26.3) | 49 (23.9) | |
| Androgen deprivation therapy | 125 (8.7) | 85 (6.9) | 40 (19.5) | |
| Other/None | 109 (7.6) | 96 (7.8) | 13 (6.3) | |
| Missing | 249 (17.4) | 191 (15.6) | 58 (28.3) | |